Skin cancer in kidney transplant recipients affected with autosomal dominant polycystic kidney disease

Jankowska, Magdalena; Dębska-Ślizień, Alicja; Imko-Walczuk, Beata; Piesiaków, Maria-Luiza; Lizakowski, Sławomir; Czarnacka, Kamila; Rutkowski, Bolesław

doi:10.1111/ctr.12707

Cited by 5 publications

(2 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Other risk factors associated with a higher incidence of NMSC are advanced age, male sex, fair skin phototype, skin cancers prior to transplantation, premalignant lesions, UV exposure, infections (HPV, EBV etc.) and also genetic disorders such as autosomal dominant polycystic kidney disease [ 4 , 5 ]. Different treatment modalities can result in not only increased incidence of cancers but also impaired organ function, mainly kidney [ 7 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Non-melanoma skin cancer outcomes in kidney transplant recipients converted from calcineurin inhibitors to mTOR inhibitors: a systematic review

Olszewska¹,

Imko-Walczuk²,

Dębska-Ślizień³

2023

pdia

View full text Add to dashboard Cite

Renal transplant recipients treated with calcineurin inhibitors (CNIs) are at a high risk of developing a skin cancer. Therefore, new therapeutic options such as inhibitors of the mammalian target of rapamycin (mTORi) have been studied to find treatment regimens decreasing the rate of skin cancers. This systematic review focuses on recent randomized controlled trials studying the impact of conversion from CNI to mTORi in renal transplant recipients on development of non-melanoma skin cancers (NMSC). Outcomes of analysed trials revealed that conversion from CNI to mTORi in post-transplant patients reduces the risk and delays the occurrence of NMSC. However, mTORi protective properties against NMSC are more effective in patients with a history of a single SCC compared with multiple SCCs. At the same time, conversion to mTORi is associated with more common discontinuations secondary to adverse events and also increased mortality. In conclusion, conversion to mTORi is protective against NMSC but given the high AE rates and therapy discontinuation there is a need to determine who would benefit from conversion and search for new treatment regimens including combination strategies with mTORi.

show abstract

Section: Introductionmentioning

confidence: 99%

“…Non-melanoma skin cancers (NMSC) are the most common malignancies in solid organ transplant recipients [1][2][3][4][5][6]. Incidence rates of post-transplantation NMSC are approximately 7% after 1 year and 10-45% after 10 years since organ transplantation [3].…”

Section: Introductionmentioning

confidence: 99%

Non-melanoma skin cancer outcomes in kidney transplant recipients converted from calcineurin inhibitors to mTOR inhibitors: a systematic review

Olszewska¹,

Imko-Walczuk²,

Dębska-Ślizień³

2023

pdia

View full text Add to dashboard Cite

show abstract

Immunosuppressants

2017

Reactions Weekly

View full text Add to dashboard Cite

ADPKD: clinical issues before and after renal transplantation

et al. 2016

View full text Add to dashboard Cite

Autosomal dominant polycystic kidney disease (ADPKD) is the first genetic cause of end-stage renal disease (ESRD) and the number of these patients who are listed for or receive a kidney transplant (KTx) is continuously increasing over time. Hence, nephrologists are involved not only in the handling of ADPKD patients during the long course of the disease, but also in programming and performing a renal transplant. The handling of all these processes implies the complete awareness of a number of critical points related to the decisions to be taken both before and after the transplant intervention. In the present review, we will briefly deal with the main critical points related to the clinical handling of the patients both before and after KTx.

show abstract

Skin cancer in kidney transplant recipients affected with autosomal dominant polycystic kidney disease

Cited by 5 publications

References 8 publications

Non-melanoma skin cancer outcomes in kidney transplant recipients converted from calcineurin inhibitors to mTOR inhibitors: a systematic review

Non-melanoma skin cancer outcomes in kidney transplant recipients converted from calcineurin inhibitors to mTOR inhibitors: a systematic review

Immunosuppressants

ADPKD: clinical issues before and after renal transplantation

Contact Info

Product

Resources

About